The gateway to oncology
Approaches to cancer treatment have transitioned from the conventional chemotherapy and radiotherapy options to a more personalised and targeted approach. As expected with personalised medicine, there are different biomarkers that can be utilised, and this adds to the level of personalisation that can be achieved. We have seen admirable advancements in recent years – particularly in pancreatic, prostate and ovarian cancers – to both include and expand beyond patient selection based on BRCA1/2 genes, which are involved in a DDR pathway known as Homologous Recombination Repair, shifting focus to a broader indication in ovarian cancer defined as Homologous Recombination Deficiency.1,3,4 We are proud to focus our attention on DDR and usher in a new era of targeted therapy, continuing to contribute to the value of precision medicine.
We have come so far in pioneering DDR research and will continue to push the boundaries of our knowledge in this important area of cancer therapy. In addition, we are committed to tackling emerging resistance and achieving more durable responses. Central to this, we are exploring the effects of DDR inhibitor combinations including those with other targeted therapies.